Two-year clinical outcomes in stable angina and acute coronary syndrome after percutaneous coronary intervention of left main coronary artery disease

Dae Young Hyun, Myung Ho Jeong, Doo Sun Sim, Yun Ah Jeong, Kyung Hoon Cho, Min Chul Kim, Hyun Kuk Kim, Hae Chang Jeong, Keun Ho Park, Young Joon Hong, Jun Han Kim, Youngkeun Ahn, and Jung Chaee Kang

Background/Aims: This study appraised the long term clinical outcomes of patients treated with percutaneous coronary intervention (PCI) for unprotected left main coronary artery (ULMCA) disease. There are limited data regarding long-term clinical outcomes after PCI for ULMCA disease.

Methods: From 2001 to 2011, a total of 448 patients who underwent PCI for ULMCA disease and had 2-year clinical follow-up, were analyzed. The study patients were divided into two groups: group I (stable angina pectoris [SAP], n = 60, 48 men, 62 ± 10 years) and group II (acute coronary syndrome [ACS], n = 388, 291 men, 64 ± 10 years). We evaluated clinical and angiographic characteristics and major adverse cardiac events (MACE) during 2-year clinical follow-up.

Results: Mean age of studied patients was 64 ± 10 years with 339 male patients. Average stent diameter was 3.6 ± 0.4 mm and stent length was 19.7 ± 6.3 mm. Stent implantation techniques and use of intravascular ultrasound guidance were not different between two groups. In-hospital mortality was 0% in group I and 7% in group II (p = 0.035). One-month mortality was 0% in group I and 7.7% in group II (p = 0.968). Two-year survival rate was 93% in the group I and 88.4% in the group II (p = 0.921). Predictive factors for 2-year MACE were hypertension, Killip class ≥ 3, and use of intra-aortic balloon pump by multivariate analysis.

Conclusions: Although in-hospital mortality rate was higher in ACS than in SAP, clinical outcomes during 2-year clinical follow-up were similar between SAP and ACS after PCI of ULMCA.

Keywords: Coronary artery disease; Left main stem; Percutaneous coronary intervention

INTRODUCTION

Unprotected left main coronary artery (ULMCA) disease takes place in 5% of patients undergoing coronary angiography [1-3]. Coronary artery bypass graft (CABG) has been the standard of care for the management of ULMCA [4-6]. In contemporary practice, percutaneous coronary intervention (PCI) has become an alternative...
strategy in patients who have ULMCA disease because of current improvements in interventional techniques and adjunctive pharmacology [7-9]. There are, however, limited and conflicting data regarding long-term outcomes of PCI for ULMCA disease, especially in patients with acute coronary syndrome (ACS).

This study evaluated the long-term clinical outcomes of patients with stable angina and ACS, who were treated with PCI for ULMCA disease.

METHODS

Patients
From 2001 to 2011, a total of 448 consecutive patients (339 men, 64 ± 10 years) were included who underwent PCI for ULMCA disease with 2-year clinical follow-up at Chonbuk National University Hospital. The patients were divided into two groups: group 1 (stable angina pectoris [SAP], n = 60, 48 men, 62 ± 10 years) and group II (ACS, n=388, 291 men, 65 ± 10 years).

PCI procedure
Before the stent was inserted, patients underwent predilation inflation of undersized balloon for immediate stent implantation. Lesion lengths and vessel reference diameter were visually evaluated by the operators [10-12]. And then, intravascular ultrasound (IVUS) was used to exactly estimate the target lesion and stent placement; 83.3% (50/60) of cases in group I and 69.3% (268/388) of cases in group II. Stenting was performed using: bare metal stents (BMS) and drug eluting stents (DES). Types of DES were paclitaxel eluting stents (PES), sirolimus eluting stents, biolimus eluting stents, zotarolimus eluting stents (ZES), and everolimus eluting stents (EES). Intra-aortic balloon pump (IABP) was used when the systolic blood pressure was below 90 mmHg despite use of inotropic agents.

Definitions
Target lesion revascularization (TLR) was defined as a repeat intervention to manage luminal stenosis anywhere within the stent. Target vessel revascularization (TVR) was defined as any reintervention driven by lesions located in the treated vessel within and beyond the target lesion limits. Non-TVR was defined as any reintervention in vessels other than the target vessel [13]. Major cardiovascular adverse event (MACE) were defined as a case including TLR, TVR, Non-TVR, CABG, myocardial infarction (MI), and death after PCI procedure.

Statistical analysis
Data processing and statistical analysis was performed using the IBM SPSS version 21 (IBM Co., Armonk, NY, USA). A p < 0.05 was considered to indicate statistical significance. The confidence intervals (CIs) for our rates are 95%. Variables were compared using either the chi-square test. The variables that were found to be significant by univariate analysis were entered into multivariate analysis using Cox regression model.

RESULTS

Clinical characteristics
Baseline clinical characteristics of the patients are summarized in Table 1. Mean age was 64 ± 10 years with 339 male patients. Significant differences were found between two groups for ejection fraction, Killip class ≥ 3, homocysteine and the levels of N-terminal prohormone brain natriuretic peptide.

Coronary angiographic and procedural findings
Baseline angiographic and procedural data are represented in Table 2. Average stent diameter was 3.6 ± 0.4 mm and stent length was 19.7 ± 6.3 mm. Stent diameter in group I was longer than that in group II (3.8 ± 0.4 mm vs. 3.6 ± 0.4 mm, p = 0.021). Group I more often received PES (51.7% vs. 32.0%, p = 0.003) whereas group II more often received ZES (1.7% vs. 11.9%, p = 0.017) and EES (3.3% vs. 18.8%, p = 0.003). IABP was used in two patients in group I (3.3% vs. 11.6%, p = 0.052) while 45 patients in group II. Fifty patients in group I used IVUS (83.3% vs. 69.0%, p = 0.073). On the other hand 267 patients in group II used IVUS.

Medical treatment during hospitalization
Patients in group I received more often aspirin (100% vs. 92.3%, p = 0.026), clopidogrel (100% vs. 91%, p = 0.015), cilostazol (85% vs. 62.6%, p = 0.001), and statin (96.7% vs. 86.1%, p = 0.021) compared with patients in group II. Five patients in group I received abciximab whereas 57

https://doi.org/10.3904/kjim.2014.373
The Korean Journal of Internal Medicine Vol. 31, No. 6, November 2016

Table 1. Baseline characteristics between stable angina and acute coronary syndrome

| Characteristic                | Group I (n = 60)       | Group II (n = 388)   | p value |
|------------------------------|------------------------|----------------------|---------|
| Age, yr                      | 62.2 ± 10.0            | 64.5 ± 10.3          | 0.110   |
| Male sex                     | 48 (80.0)              | 291 (75.0)           | 0.401   |
| Diabetes                     | 22 (36.7)              | 128 (33.0)           | 0.574   |
| Hypertension                 | 28 (46.7)              | 192 (49.5)           | 0.685   |
| Familial history             | 1 (1.7)                | 10 (2.6)             | 0.671   |
| Dyslipidemia                 | 22 (36.7)              | 103 (26.5)           | 0.104   |
| Smoking                      | 16 (26.7)              | 150 (38.7)           | 0.073   |
| Body mass index, kg/m²       | 24.3 ± 2.9             | 23.8 ± 3.3           | 0.321   |
| Ejection fraction, %         | 63.0 ± 10.8            | 59.4 ± 13.1          | 0.022   |
| Killip class ≥ 3             | 0                      | 44 (11.3)            | 0.006   |
| SBP, mmHg                    | 122.1 ± 22.3           | 118.1 ± 24.1         | 0.227   |
| DBP, mmHg                    | 75.4 ± 9.5             | 72.7 ± 14.2          | 0.053   |
| Total cholesterol, mg/dL     | 171.2 ± 35.3           | 176.1 ± 44.3         | 0.422   |
| Triglyceride, mg/dL          | 113.1 ± 85.5           | 114.5 ± 63.8         | 0.881   |
| HDL-C, mg/dL                 | 45.0 ± 11.6            | 43.8 ± 11.8          | 0.487   |
| LDL-C, mg/dL                 | 111.3 ± 33.3           | 113.9 ± 40.1         | 0.637   |
| Lipoprotein(a), mg/dL        | 30.1 ± 23.2            | 33.3 ± 28.3          | 0.426   |
| Glucose, mg/dL               | 140.0 ± 69.1           | 146.5 ± 76.0         | 0.543   |
| Creatinine, mg/dL            | 1.0 ± 0.7              | 1.1 ± 0.9            | 0.556   |
| Homocysteine, μmol/L         | 9.0 ± 3.4              | 10.7 ± 6.6           | 0.005   |
| hs-CRP, mg/L                 | 0.4 ± 1.0              | 3.7 ± 31.3           | 0.414   |
| NT-ProBNP, pg/mL             | 321.9 ± 554.0          | 2,324.3 ± 5,953.8    | 0.001   |
| Fibrinogen, mg/dL            | 284.1 ± 87.7           | 388.7 ± 1,503.4      | 0.594   |
| Troponin-I, ng/mL            | 0.05 ± 0.02            | 7.7 ± 22.3           | 0.001   |
| CK, IU/L                     | 118.8 ± 104.8          | 343.6 ± 878.3        | 0.001   |
| CK-MB, ng/mL                 | 2.1 ± 2.7              | 27.3 ± 83.5          | 0.001   |
| Hemoglobin, g/dL             | 12.9 ± 1.6             | 13.2 ± 7.3           | 0.774   |
| Platelet, 10³/mm³            | 211.0 ± 60.5           | 226.7 ± 66.9         | 0.120   |

Values are presented as mean ± SD or number (%).
SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; NT-ProBNP, N-terminal prohormone brain natriuretic peptide; CK, creatine kinase; CK-MB, creatine kinase-MB.

in group II received abciximab (8.3% vs. 14.8%, p = 0.178).

In-hospital clinical outcomes
During hospitalization, group I more often received aspirin (100% vs. 92.3%, p = 0.026), clopidogrel (100% vs. 91%, p = 0.015), cilostazol (85% vs. 62.6%, p = 0.001), and statin (96.7% vs. 86.1%, p = 0.021) compared to group II. In-hospital death occurred more frequently inpatients in group II than in group I (6% vs. 7%, p = 0.035) (Table 3).

One-month clinical outcome
In group I there was no death. On the other hand, in group II there were 30 deaths (6% vs. 7%, p = 0.968). Other adverse events in group I consisted of TLR in one patient [10]. Four TLR also occurred in group II (1.7% vs. 1.0%, p = 0.697).

One-year clinical outcome
One-year survival rate was 96.7% (38/60) in the group I.
Table 2. Procedural characteristics and medical treatment during hospitalization between stable angina and acute coronary syndrome

| Characteristic                        | Group I (n = 60) | Group II (n = 388) | \( p \) value |
|---------------------------------------|------------------|--------------------|---------------|
| IABP                                  | 2 (3.3)          | 45 (11.6)          | 0.052         |
| Drug eluting stents                   | 52 (86.7)        | 336 (86.6)         | 0.988         |
| PES                                   | 31 (51.7)        | 124 (32.0)         | 0.003         |
| SES                                   | 18 (30.0)        | 94 (24.2)          | 0.337         |
| BES                                   | 0                | 5 (1.3)            | 0.377         |
| ZES                                   | 1 (1.7)          | 46 (11.9)          | 0.017         |
| EES                                   | 2 (3.3)          | 73 (18.8)          | 0.003         |
| Stent diameter, mm                    | 3.8 ± 0.4        | 3.6 ± 0.4          | 0.021         |
| Stent length, mm                      | 20.1 ± 6.9       | 19.6 ± 6.2         | 0.571         |
| Treated vessel                        |                  |                    |               |
| LM only                               | 9 (15.0)         | 42 (10.8%)         | 0.343         |
| LM-LAD                                | 28 (46.7)        | 171 (44.1)         | 0.707         |
| LM-LCX                                | 1 (1.7)          | 24 (6.2)           | 0.156         |
| LM-LAD-LCX                            | 21 (35)          | 147 (37.9)         | 0.667         |
| Stenting technique                    |                  |                    |               |
| Crushing                              | 1 (1.7)          | 14 (3.6)           | 0.437         |
| Kissing                               | 4 (6.7)          | 15 (3.9)           | 0.316         |
| T stent                               | 2 (3.3)          | 26 (6.7)           | 0.316         |
| Cross-over                            | 43 (71.7)        | 286 (73.7)         | 0.739         |
| Directing stenting                    | 6 (10.0)         | 42 (10.8)          | 0.848         |
| IVUS                                  | 50 (83.3)        | 267 (69.0)         | 0.073         |
| Pre-PCI TIMI 0–1                      | 0                | 24 (6.2)           | 0.048         |
| Post-PCI TIMI 3                       | 41 (68.3)        | 293 (75.5)         | 0.235         |
| Medications during hospitalization    |                  |                    |               |
| Aspirin                               | 60 (100)         | 358 (92.3)         | 0.026         |
| Clopidogrel                           | 60 (100)         | 353 (91)           | 0.015         |
| Cilostazol                            | 51 (85)          | 243 (62.6)         | 0.001         |
| Statin                                | 58 (96.7)        | 334 (86.1)         | 0.021         |
| β-Blocker                             | 49 (81.7)        | 280 (74.5)         | 0.229         |
| CCB                                   | 13 (21.7)        | 60 (15.5)          | 0.226         |
| ACEi/ARB                              | 40 (83.1)        | 238 (62.5)         | 0.086         |
| Glycoprotein IIb/IIIa inhibitor (abciximab) | 5 (8.3)   | 57 (14.8)          | 0.178         |
| Heparin                               | 50 (83.3)        | 319 (82.2)         | 0.833         |
| LMWH                                  | 9 (15.0)         | 64 (16.8)          | 0.721         |

Values are presented as number (%) or mean ± SD.

IABP, intra-aortic balloon pump; PES, paclitaxel eluting stent; SES, sirolimus eluting stent; BES, biolimus eluting stent; ZES, zotarolimus eluting stent; EES, everolimus eluting stent; LM, left main; LAD, left anterior descending; LCX, left circumflex artery; IVUS intravascular ultrasound; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction; CCB, calcium channel blocker; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; LMWH, low molecular weight heparin.
Table 3. Clinical outcome between stable angina and acute coronary syndrome in patients with left main coronary artery

| Variable             | Group I (n = 60) | Group II (n = 388) | p value |
|----------------------|------------------|--------------------|---------|
| In hospital death    | 0                | 27 (7.0)           | 0.035   |
| 30 Days              |                  |                    |         |
| Death                | 0                | 30 (7.7)           | 0.968   |
| Myocardial infarction| 0                | 0                  | -       |
| TLR                  | 1 (1.7)          | 4 (1.0)            | 0.697   |
| TVR                  | 1 (1.7)          | 4 (1.1)            | 0.697   |
| Non-TVR              | 0                | 0                  | -       |
| CABG                 | 0                | 0                  | -       |
| MACE                 | 1 (1.7)          | 33 (8.5)           | 0.540   |
| 1 Year               |                  |                    |         |
| Death                | 2 (3.3)          | 38 (9.8)           | 0.718   |
| Myocardial infarction| 0                | 1 (0.3)            | 0.794   |
| TLR                  | 8 (13.3)         | 46 (11.9)          | 0.060   |
| TVR                  | 8 (13.3)         | 48 (12.4)          | 0.965   |
| Non-TVR              | 1 (1.7)          | 6 (1.5)            | 0.989   |
| CABG                 | 1 (1.7)          | 1 (0.3)            | 0.208   |
| MACE                 | 9 (15.0)         | 90 (23.2)          | 0.858   |
| 2 Years              |                  |                    |         |
| Death                | 4 (6.7)          | 45 (11.6)          | 0.921   |
| Myocardial infarction| 0                | 1 (0.3)            | 0.794   |
| TLR                  | 8 (13.3)         | 55 (14.2)          | 0.623   |
| TVR                  | 9 (15.0)         | 57 (14.7)          | 0.687   |
| Non-TVR              | 1 (1.7)          | 8 (2.1)            | 0.779   |
| CABG                 | 1 (1.7)          | 2 (0.5)            | 0.370   |
| MACE                 | 12 (20.0)        | 101 (26.0)         | 0.894   |

Values are presented as number (%).
TLR, target lesion revascularization; TVR, target vessel revascularization; CABG, coronary artery bypass graft; MACE, major adverse cardiac event.

Figure 1. Two-year major adverse cardiac event (MACE)-free survivals were not different between stable angina pectoris (SAP) and acute coronary syndrome (ACS) in patients with unprotected left main coronary artery disease. PCI, percutaneous coronary intervention.
and 90.2% (350/388) in the group II (p = 0.718). CABG was carried out in two patients. One patient in group I was expired on the following day, right after operation. The other patient in group II still alive and follow-up regularly. The clinical outcomes of 12-month MACE between stable angina and ACS were similar (p = 0.858) (Fig. 1).

Table 4. Univariate and multivariate analysis for predictors of 2-year mortality in patients with unprotected left main coronary artery disease

| Variable                | Univariate analysis | Multivariate analysis |
|-------------------------|---------------------|-----------------------|
|                         | HR (95% CI)         | p value | HR (95% CI) | p value |
| Age > 65 years          | 1.983 (1.101–3.571) | 0.023   | -           | -       |
| Sex                     | 0.337 (0.134–0.850) | 0.021   | -           | -       |
| Group                   | 1.830 (0.658–5.089) | 0.247   | -           | -       |
| BMI ≥ 25 kg/m²          | 1.347 (0.767–2.365) | 0.300   | -           | -       |
| Diabetes                | 1.292 (0.727–2.293) | 0.383   | -           | -       |
| Hypertension            | 2.243 (1.235–4.076) | 0.008   | 2.625 (1.377–5.002) | 0.003 |
| Familial history        | 0.048 (0–123.140)   | 0.448   | -           | -       |
| Dyslipidemia            | 0.483 (0.226–1.030) | 0.060   | -           | -       |
| Smoking                 | 0.890 (0.498–1.614) | 0.715   | -           | -       |
| EF < 40%                | 4.232 (2.243–7.985) | 0.001   | -           | -       |
| Killip score ≥ 3        | 13.582 (7.721–23.890) | 0.001 | 6.564 (2.938–14.665) | 0.001 |
| LM only                 | 1.119 (0.476–2.629) | 0.796   | -           | -       |
| LM-LAD                  | 0.860 (0.486–1.520) | 0.604   | -           | -       |
| LM-LCX                  | 1.111 (0.346–3.572) | 0.860   | -           | -       |
| LM-LAD-LCX              | 1.029 (0.579–1.829) | 0.922   | -           | -       |
| SBP < 100 mmHg          | 7.684 (4.367–13.519) | 0.001 | -           | -       |
| IVUS                    | 0.270 (0.153–0.476) | 0.001   | -           | -       |
| Abciximab               | 2.801 (1.507–5.207) | 0.001   | -           | -       |
| Heparin                 | 1.085 (0.509–2.315) | 0.832   | -           | -       |
| LMWH                    | 0.717 (0.305–1.687) | 0.446   | -           | -       |
| Pre-PCI TIMI < 2        | 14.211 (7.685–26.280) | 0.001 | -           | -       |
| Post-PCI TIMI ≥ 3       | 0.512 (0.288–0.909) | 0.022   | -           | -       |
| Creatinine ≥ 2.0 mg/dL  | 3.327 (1.492–7.420) | 0.003   | -           | -       |
| Aspirin                 | 0.028 (0.016–0.051) | 0.001   | -           | -       |
| Clopidogrel             | 0.038 (0.022–0.068) | 0.001   | -           | -       |
| Cilostazol              | 0.245 (0.136–0.442) | 0.001   | -           | -       |
| Statin                  | 0.095 (0.054–0.167) | 0.001   | -           | -       |
| β-Blocker               | 0.144 (0.080–0.259) | 0.001   | -           | -       |
| CCB                     | 0.685 (0.292–1.609) | 0.385   | -           | -       |
| ARB or ACEi             | 0.285 (0.148–0.548) | 0.001   | -           | -       |

HR, hazard ratio; CI, confidence interval; BMI, body mass index; EF, ejection fraction; IABP, intra-aortic balloon pump; LM, left main; LAD, left anterior descending; LCX, left circumflex artery; SBP, systolic blood pressure; IVUS, intravascular ultrasound; LMWH, low molecular weight heparin; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction; CCB, calcium channel blocker; ARB, angiotensin receptor blocker; ACEi, angiotensin converting enzyme inhibitor.
Two-year clinical outcome

Two-year survival rate was 93.3% (56/60) in the group I patients and 88.4% (343/388) in the group II patients (p = 0.921). On multivariate analysis, independent predictors of 2-year mortality were hypertension (hazard ratio [HR], 2.63; 95% CI, 1.38 to 5.00; p = 0.003), Killips class ≥ 3 (HR, 6.56; 95% CI, 2.94 to 14.67; p = 0.001), and use of IABP (HR, 6.564; 95% CI, 1.60 to 7.70; p = 0.002) (Table 4).

When we reanalyzed the data by including clinical diagnoses of ACS, 2-year MACE-free survival rate was not different among SAP, unstable angina pectoris (UAP), ST elevation myocardial infarction (STEMI), non-STEMI in patients with ULMCA disease (Fig. 2). Among ACS patients, however, 2-year MACE-free survival was significantly lower in STEMI compared to UAP (p = 0.012) (Fig. 3).

DISCUSSION

Significant ULMCA disease is a high-risk lesion that compromises blood flow to approximately 75% of the heart. Its incidence rate in undergoing PCI is 2.5% to 10%, and typically it exists with other significant narrowing of the coronary tree. The author compared of 2-year clinical outcomes in patients with stable angina and ACS after PCI of ULMCA disease. In general, ACS would show poorer prognosis compared with stable angina after PCI. In the present study, patients were divided into SAP and ACS groups. Interestingly 2-year clinical outcome of ULMCA disease after PCI was similar between the two groups.

The result of the present study is in general consistent with the previous studies on outcome of ULMCA disease with comparable 1-year mortality. In our study, major cardiovascular events developed 3.3% in patients with stable angina and 7.7% in patients with ACS. Ferrante et al. [14] reported major cardiac events developed in patients with ULMCA disease were 19.6% after DES implantation and 29.1% after BMS implantation. Sim et al. [15] reported major cardiac events developed 18% in patients with culprit left main coronary artery (LMCA) and 13.8% with non-culprit LMCA.

Ferrante et al. [14] study, out of 227 patients undergoing PCI for ULMCA. One hundred and forty-eight patients were treated with DES and 79 patients were treated with BMS. At 12 months follow-up, 29 patients (19.6%) with DES versus 23 patients (29.1%) with BMS died. Fajadet and Chieffo [16] revealed no distinction in the result of MACE and cerebrovascular events between
PCI and CABG in ULMCA at 5-year clinical follow-up.

Naik et al. [17] recently presented a meta-analysis of PCI versus CABG in patients with ULMCA disease. This study also identified no difference in death or MACE or cerebrovascular events.

Sim et al. [15] compared outcome of culprit ULMCA (n = 256) and non-culprit ULMCA (n = 331) in patients with acute MI. Patients with culprit LMCA were younger and more likely to have Killip class ≥ 3, cardiopulmonary resuscitation at admission, low blood pressure, and increased heart rate. Patients with culprit LMCA had less complex lesions, more isolated LMCA disease, a lower rate of post-PCI thrombolysis in MI flow 3, and were more likely to receive DES. In both groups, PCI was more frequently used than CABG. Among patients receiving revascularization therapy, early and 12-month clinical outcomes were similar between PCI and CABG. Patients with culprit LMCA had significantly higher in-hospital mortality. However, clinical outcomes at 30 days and 12 months were similar between the two groups. On the contrary, Palmerini et al. [18] showed 2-year survival rate free from cardiac mortality and MI in patients with ACS was lower than that in patients with SAP (86% vs. 96%, \( p < 0.00001 \)).

Regarding the choice between PCI and CABG for ULMCA disease, this study suggested that the ideal patient for PCI would have no hypertension, Killip score ≤ 2. The use of PCI for these select patients can improve cardiovascular outcomes and is a reasonable revascularization strategy.

The limitations of this study are that we did not show data on clinical follow-up beyond 2 years to document longer-term safety. The study is retrospective and is therefore subject to the limitations pertinent to this type of clinical investigation.

**KEY MESSAGE**

1. In patients with unprotected left main coronary artery (ULMCA) disease undergoing percutaneous coronary intervention (PCI), in-hospital mortality rate was higher in acute coronary syndrome (ACS) than in stable angina pectoris (SAP).
2. Two-year clinical outcome was similar between SAP and ACS. Therefore, PCI of ULMCA can be performed in patients with ACS effectively and safely.
3. Predictive factors of 2-year mortality were hypertension, Killip class ≥ 3 and use of intra-aortic balloon pump.

**Conflict of interest**

No potential conflict of interest relevant to this article was reported.

**REFERENCES**

1. El-Menyar AA, Al Suwaidi J, Holmes DR Jr. Left main coronary artery stenosis: state-of-the-art. Curr Probl Cardiol 2007;32:103-193.
2. Black A, Cortina R, Bossi I, Choussat R, Fajadet J, Marco J. Unprotected left main coronary artery stenting: correlates of midterm survival and impact of patient selection. J Am Coll Cardiol 2001;37:832-838.
3. Waller BF. Atherosclerotic and nonatherosclerotic coronary artery factors in acute myocardial infarction. Cardiovasc Clin 1989;20:29-104.
4. Gomez-Lara J, Roura G, Blasco-Lucas A, et al. Global risk score for choosing the best revascularization strategy in patients with unprotected left main stenosis. J Invasive Cardiol 2013;25:650-658.
5. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, et al. Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501-2555.
6. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SACI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 2012;59:859-881.
7. Cheng CI, Lee FY, Chang JP, et al. Long-term outcomes of intervention for unprotected left main coronary artery
stenosis: coronary stenting vs coronary artery bypass grafting. Circ J 2009;73:705-712.
8. Cheng CI, Hsueh SK, Lee FY, et al. Clinical presentation and prognostic factors of patients with acute ST-segment elevation myocardial infarction following emergent revascularization for left main coronary artery obstruction. Circ J 2008;72:1598-1604.
9. Cheng CI, Wu CJ, Fang CY, et al. Feasibility and safety of transradial stenting for unprotected left main coronary artery stenoses. Circ J 2007;71:855-861.
10. Montalescot G, Brieger D, Eagle KA, et al. Unprotected left main revascularization in patients with acute coronary syndromes. Eur Heart J 2009;30:2308-2317.
11. Silvestri M, Barragan P, Sainsous J, et al. Unprotected left main coronary artery stenting: immediate and medium-term outcomes of 140 elective procedures. J Am Coll Cardiol 2000;35:1543-1550.
12. Sim DS, Jeong MH, Ahn Y, et al. Effectiveness of drug-eluting stents versus bare-metal stents in large coronary arteries in patients with acute myocardial infarction. J Korean Med Sci 2011;26:521-527.
13. Karjalainen PP, Annala AP, Ylitalo A, Vahlberg T, Airaksinen KE. Long-term clinical outcome with titanium-ni-tride-oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population. Int J Cardiol 2016;144:42-46.
14. Ferrante G, Presbitero P, Valgimigli M, et al. Percutaneous coronary intervention versus bypass surgery for left main coronary artery disease: a meta-analysis of randomised trials. EuroIntervention 2011;7:738-746.
15. Sim DS, Ahn Y, Jeong MH, et al. Clinical outcome of unprotected left main coronary artery disease in patients with acute myocardial infarction. Int Heart J 2013;54:185-191.
16. Fajadet J, Chieffo A. Current management of left main coronary artery disease. Eur Heart J 2012;33:336-50.
17. Naik H, White AJ, Chakravarty T, et al. A meta-analysis of 3,773 patients treated with percutaneous coronary intervention or surgery for unprotected left main coronary artery stenosis. JACC Cardiovasc Interv 2009;2:739-747.
18. Palmerini T, Sangiorgi D, Marzocchi A, et al. Impact of acute coronary syndromes on two-year clinical outcomes in patients with unprotected left main coronary artery stenosis treated with drug-eluting stents. Am J Cardiol 2016;105:174-178.